KR920009397A - 사람 레트로바이러스의 복제를 억제하는데 효과적인 약제를 제조하기 위한 크산틴의 용도 - Google Patents
사람 레트로바이러스의 복제를 억제하는데 효과적인 약제를 제조하기 위한 크산틴의 용도 Download PDFInfo
- Publication number
- KR920009397A KR920009397A KR1019910019714A KR910019714A KR920009397A KR 920009397 A KR920009397 A KR 920009397A KR 1019910019714 A KR1019910019714 A KR 1019910019714A KR 910019714 A KR910019714 A KR 910019714A KR 920009397 A KR920009397 A KR 920009397A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- group
- formula
- carbon atoms
- chem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241001430294 unidentified retrovirus Species 0.000 title claims abstract 5
- 230000010076 replication Effects 0.000 title claims abstract 4
- 230000002401 inhibitory effect Effects 0.000 title claims abstract 3
- 239000003814 drug Substances 0.000 title claims 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 3
- 229940075420 xanthine Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 21
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract 4
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract 2
- 208000031886 HIV Infections Diseases 0.000 claims abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract 2
- 229930195733 hydrocarbon Natural products 0.000 claims abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- HJPRDDKCXVCFOH-UHFFFAOYSA-N 1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1N(CC(C)=O)C=N2 HJPRDDKCXVCFOH-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 1
- 238000010586 diagram Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000005188 oxoalkyl group Chemical group 0.000 claims 1
- 229960001476 pentoxifylline Drugs 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 241000282412 Homo Species 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61023090A | 1990-11-07 | 1990-11-07 | |
| US07/610,230 | 1990-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR920009397A true KR920009397A (ko) | 1992-06-25 |
Family
ID=24444220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019910019714A Ceased KR920009397A (ko) | 1990-11-07 | 1991-11-07 | 사람 레트로바이러스의 복제를 억제하는데 효과적인 약제를 제조하기 위한 크산틴의 용도 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0484785B1 (enExample) |
| JP (1) | JPH054922A (enExample) |
| KR (1) | KR920009397A (enExample) |
| AT (1) | ATE138266T1 (enExample) |
| AU (1) | AU649278B2 (enExample) |
| CA (1) | CA2055041A1 (enExample) |
| DE (1) | DE69119700T2 (enExample) |
| DK (1) | DK0484785T3 (enExample) |
| ES (1) | ES2087205T3 (enExample) |
| GR (1) | GR3020017T3 (enExample) |
| HU (1) | HUT61468A (enExample) |
| IE (1) | IE913879A1 (enExample) |
| IL (1) | IL99966A0 (enExample) |
| PT (1) | PT99434A (enExample) |
| TW (1) | TW209169B (enExample) |
| ZA (1) | ZA918801B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59304710D1 (de) * | 1992-02-22 | 1997-01-23 | Hoechst Ag | Verwendung von Xanthinderivaten zur Behandlung von Muskelschädigungen nach vollständiger Unterbrechung der Blutzirkulation |
| US7067148B2 (en) | 2001-02-15 | 2006-06-27 | King Pharmaceutical Research & Development, Inc. | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| ES2275400B1 (es) * | 2005-04-20 | 2008-04-01 | Universidad Autonoma De Madrid | Uso de compuestos agonistas de la actividad tubulina desacetilasa de la proteina hdac6 en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y sus aplicaciones en el tratamiento de infecciones virales. |
| EP2265334A2 (en) | 2008-02-29 | 2010-12-29 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| EP2473052A4 (en) | 2009-09-02 | 2013-03-20 | Concert Pharmaceuticals Inc | SUBSTITUTED XANTHINE DERIVATIVES |
| US20130324564A1 (en) | 2010-09-01 | 2013-12-05 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)-dione |
| WO2013013052A1 (en) | 2011-07-19 | 2013-01-24 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| CN104364255A (zh) | 2012-04-13 | 2015-02-18 | 康塞特医药品有限公司 | 取代的黄嘌呤衍生物 |
| WO2013159006A1 (en) | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3737433A (en) * | 1964-09-05 | 1973-06-05 | Albert Ag Chem Werke | Certain oxoalkyldimethylxanthines |
| CH608236A5 (enExample) * | 1974-01-22 | 1978-12-29 | Wuelfing J A Fa | |
| US4663317A (en) * | 1984-04-18 | 1987-05-05 | Board Of Regents, University Of Texas System | Methods and compositions for treating viral infections |
| US4636507A (en) * | 1984-04-30 | 1987-01-13 | Hoechst-Roussel Pharmaceuticals Inc. | Host defense mechanism enhancement |
| DE3525801A1 (de) * | 1985-07-19 | 1987-01-22 | Hoechst Ag | Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung |
| GB8610136D0 (en) * | 1986-04-25 | 1986-05-29 | Wellcome Found | Compounds |
| DE3725554A1 (de) * | 1987-08-01 | 1989-02-09 | Hoechst Ag | Pharmazeutisches kombinationspraeparat sowie dessen herstellung und verwendung |
-
1991
- 1991-10-28 ES ES91118347T patent/ES2087205T3/es not_active Expired - Lifetime
- 1991-10-28 DK DK91118347.3T patent/DK0484785T3/da active
- 1991-10-28 EP EP91118347A patent/EP0484785B1/en not_active Expired - Lifetime
- 1991-10-28 AT AT91118347T patent/ATE138266T1/de not_active IP Right Cessation
- 1991-10-28 DE DE69119700T patent/DE69119700T2/de not_active Expired - Fee Related
- 1991-11-05 AU AU86998/91A patent/AU649278B2/en not_active Ceased
- 1991-11-05 IL IL99966A patent/IL99966A0/xx unknown
- 1991-11-06 PT PT99434A patent/PT99434A/pt not_active Application Discontinuation
- 1991-11-06 IE IE387991A patent/IE913879A1/en not_active Application Discontinuation
- 1991-11-06 CA CA002055041A patent/CA2055041A1/en not_active Abandoned
- 1991-11-06 ZA ZA918801A patent/ZA918801B/xx unknown
- 1991-11-06 JP JP3289900A patent/JPH054922A/ja active Pending
- 1991-11-07 HU HU913502A patent/HUT61468A/hu unknown
- 1991-11-07 KR KR1019910019714A patent/KR920009397A/ko not_active Ceased
-
1992
- 1992-01-25 TW TW081100520A patent/TW209169B/zh active
-
1996
- 1996-05-23 GR GR960401329T patent/GR3020017T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2055041A1 (en) | 1992-05-08 |
| GR3020017T3 (en) | 1996-08-31 |
| DE69119700D1 (de) | 1996-06-27 |
| JPH054922A (ja) | 1993-01-14 |
| AU649278B2 (en) | 1994-05-19 |
| DE69119700T2 (de) | 1996-11-07 |
| HUT61468A (en) | 1993-01-28 |
| ZA918801B (en) | 1992-12-30 |
| IE913879A1 (en) | 1992-05-20 |
| IL99966A0 (en) | 1992-08-18 |
| AU8699891A (en) | 1992-05-14 |
| HU913502D0 (en) | 1992-01-28 |
| PT99434A (pt) | 1992-09-30 |
| EP0484785B1 (en) | 1996-05-22 |
| EP0484785A3 (en) | 1992-12-16 |
| DK0484785T3 (da) | 1996-09-23 |
| ATE138266T1 (de) | 1996-06-15 |
| TW209169B (enExample) | 1993-07-11 |
| ES2087205T3 (es) | 1996-07-16 |
| EP0484785A2 (en) | 1992-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2083500T3 (es) | Una composicion de aminoglicosidos con una nefrotoxicidad sustancialmente reducida, inducida por el aminoglicosido. | |
| ES8308314A1 (es) | Procedimiento para preparar derivados de 2-amino-4-hidroxiquinazolina. | |
| KR920009397A (ko) | 사람 레트로바이러스의 복제를 억제하는데 효과적인 약제를 제조하기 위한 크산틴의 용도 | |
| KR910015575A (ko) | 1H-이미다조[4,5-c]퀴놀린-4-아민 | |
| KR950000728A (ko) | 포스포네이트 뉴클레오티드 에스테르 유도체 | |
| KR890003761A (ko) | 치료학적 아시클릭 뉴클레오시드 | |
| NO20013379D0 (no) | 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler | |
| ES468119A1 (es) | Un procedimiento para la preparacion de triazinas | |
| KR880013937A (ko) | 옥세타노신 유도체 | |
| KR920009399A (ko) | 면역 억제 활성을 갖는 약제를 제조하기 위한 크산틴의 용도 | |
| KR910004591A (ko) | 헤테로 고리 화합물 | |
| KR920009398A (ko) | 사람의 이인자형 이식반응 영향을 억제하는데 효과적인 약제를 제조하기 위한 크산틴의 용도 | |
| ATE126820T1 (de) | Wässrige autoxidativ trocknende alkydzusammensetzung. | |
| DK0557876T3 (da) | Anvendelse af xanthinderivater til behandling af muskelskader efter fuldstændig afbrydelse af blodcirkulationen | |
| SE8100946L (sv) | Nya indanderivat, sett att framstella dem, anvendning derav som farmaceutika och farmaceutiska kompositioner som innehaller dess derivat | |
| KR910004621A (ko) | 신규 화합물 | |
| ES342459A1 (es) | Procedimiento para la obtencion de derivados de la teofili-na. | |
| CO5150148A1 (es) | Derivados glicopeptidicos y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19911107 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19940530 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19911107 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19970818 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 19971031 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 19970818 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |